MSMatthew D. Simon

Matthew D. Simon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthew D. Simon has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The histone deacetylase inhibitor romidepsin increases cellular acetyl-methyllysine

    by Charlie L. Brown, Andreas P. Pintado-Urbanc, Aurora A. Miranda, Yeil Kim, Joshua T. Young, Matthew D. Simon

  • Open Access

    Investigation of TRMT61B methyltransferase activity on mRNA and its effects on translation

    by Dorthy Fang, John M Babich, Ryan Stanton, Isaac W Vock, Kyrillos Abdallah, Mingyi Zhu, Raj Letchuman, Richard Li, Matthew D Simon, Wendy V Gilbert, et al.

    Despite recent advances in technology to map RNA chemical modifications transcriptome-wide, the distribution of N1-methyladenosine (m1A) in messenger RNA (mRNA) remains contested, hindering a clear understanding of its function. Additionally, the enzyme(s) that installs the majority of reported mRNA m1A sites has yet to be identified. In this study, we characterized TRMT61B, an m1A methyltransferase known to methylate mitochondrial RNAs, but whose sequence preferences have been underexplored. By integrating cellular overexpression of TRMT61B and in vitro methylation of a synthetic pool of diverse human mRNA sequences, we identified a preference for a YMRA consensus motif in single-stranded RNA regions. In these experiments, TRMT61B methylated thousands of novel human mRNA sites, revealing activity on cytosolic mRNAs. We used these novel m1A-modifiable sequences to test the effects of m1A on translation of luciferase reporters and on ribosome recruitment to modified transcripts in the pool. We found that m1A addition can significantly affect translation and ribosome recruitment, but that these effects vary by transcript. Taken together, our results inform future studies of TRMT61B and mRNA modifications, and emphasize that studies of m1A regulation of mRNA must be carried out and interpreted in a highly context-aware manner.


  • Open Access

    Histone H4 acetyl-methyllysine marks accessible chromatin that resists compaction

    by Andreas P Pintado-Urbanc, Charlie L Brown, Leah J Connor, Joshua T Young, Yeil Kim, Elizabeth Black, Lilian Kabeche, Matthew Simon

    Certain regulatory DNA regions remain accessible even under conditions of widespread chromatin compaction. These regions are often marked by specific protein factors and histone modifications that help maintain their accessibility. Here, we examine the genomic landscape of acetyl-methyllysine (Kacme), a recently discovered histone post-translational modification. Across multiple systems, Kacme is highly enriched at sites of accessible chromatin, including active promoters, enhancers, silencers, and CTCF-binding sites. We find that Kacme is selectively retained at loci that resist condensation during mitosis, marks XIST and escapee regions on the inactive X chromosome in female cells and demarcates the boundaries of broad heterochromatin domains. Kacme-marked insulator elements block heterochromatin spreading and protect adjacent genes from transcriptional repression, even when H3K27me3 levels are pharmacologically elevated through KDM6A/6B inhibition. Taken together, our findings establish the chromatin features associated with Kacme and support a model in which Kacme helps safeguard chromatin accessibility at loci that resist compaction.


  • Open Access

    Investigation of TRMT61B methyltransferase activity on mRNA and its effects on translation

    by Dorthy Fang, John M. Babich, Ryan Stanton, Isaac W. Vock, Kyrillos Abdallah, Mingyi Zhu, Richard Li, Matthew D. Simon, Wendy V. Gilbert, Sigrid Nachtergaele

    Despite recent advances in technology to map RNA chemical modifications transcriptome-wide, the distribution of N¹-methyladenosine (m¹A) in mRNA remains contested, hindering a clear understanding of its function. Additionally, the enzyme(s) that installs the majority of reported mRNA m 1 A sites has yet to be identified. In this study, we characterized TRMT61B, an m 1 A methyltransferase known to methylate mitochondrial RNAs, but whose sequence preferences have been underexplored. By integrating cellular overexpression of TRMT61B and in vitro methylation of a synthetic pool of diverse human RNA sequences, we identified a preference for a YMR A consensus motif in single stranded RNA regions. In these experiments, TRMT61B methylated thousands of novel human mRNA sites, revealing activity on cytosolic mRNAs. We used these novel m 1 A-modifiable sequences to test the effects of m 1 A on translation of luciferase reporters and on ribosome recruitment to modified transcripts in the pool. We found that m 1 A addition can significantly affect translation and ribosome recruitment, but that these effects are vary by transcript. Taken together, our results can inform future studies of TRMT61B and mRNA, and emphasize that studies of m 1 A regulation of mRNA must be carried out and interpreted in a highly context-aware manner.


  • RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and Wnt pathway activation

    by Madeline Y. Mayday, Giulia Biancon, Manyi Wei, Christian Ramirez, Irene Moratti, Andreas P. Pintado-Urbanc, Jether Amos Espinosa, Mi Chen, Lin Wang, Matthew D. Simon, et al.

    The recurrent t(1;22) translocation in acute megakaryoblastic leukemia (AMKL) encodes the RBM15-MKL1 fusion protein. Dysregulation of the N6-methyladenosine (m6A) modification affects RNA fate and is linked to oncogenesis. Because RBM15 is critical for bringing the m6A writer complex to specific RNAs, we hypothesized that RM disrupts the m6A modification, thereby altering the RNA fate to drive leukemogenesis in RM-AMKL. Using a multiomics approach, we showed for the first time, to our knowledge, that RM retains the RNA-binding and m6A-modifying functions of RBM15 while also selectively regulating distinct messenger RNA targets, including Frizzled genes, in the Wnt signaling pathway. Treating murine RM-AMKL cells with the methyltransferase 3 (METTL3) inhibitor STM3675, which decreases m6A deposition, induced apoptosis in vitro and prolonged survival in transplanted mice. Frizzled genes were upregulated by RM and downregulated upon METTL3 inhibition, implicating an m6A-dependent mechanism in their dysregulation. Direct Frizzled knockdown reduced RM-AMKL growth in vitro and in vivo, highlighting Wnt signaling as a key oncogenic driver. Elevated Wnt pathway activity and Frizzled expression in multiple forms of human AMKL underscores the relevance of our findings. Together, our results establish that RM-specific m6A modifications and Wnt pathway activation are critical drivers of RM-AMKL, thereby identifying these pathways as potential therapeutic targets.


  • Open Access

    RNADecayCafe, a uniformly processed atlas of RNA half-life estimates across multiple human cell lines

    by Isaac W. Vock, Dié Tang, Antonio J. Giraldez, Matthew D Simon

    RNA expression levels are partially determined by RNA stabilities. Long-lived RNAs accumulate to higher levels than rapidly degraded RNAs when transcribed at the same rate. The extent to which RNA decay contributes to differences in gene expression between genes in the same cell or between different cell types has not been extensively examined. This is in part because reproducible RNA half-life estimates from different biological contexts have not been broadly collected and curated. To address this, we have developed RNAdecayCafe, a database of high-quality RNA half-life estimates in multiple human cell lines. RNAdecayCafe makes use of pulse-label nucleotide recoding RNA-seq data (namely SLAM-seq and TimeLapse-seq), which we found to provide consistent and orthogonally validated half-life estimates. In total, RNAdecayCafe provides half-life estimates from 11 different human cell lines across 15 datasets and a total of 64 samples that were uniformly processed with a set of optimized bioinformatic tools we recently developed (the EZbakR suite). We showcase how this resource reveals the previously underappreciated role of RNA stability in shaping gene expression. RNAdecayCafe will provide a robust database for future studies of RNA decay.


  • Open Access

    MYOD represses gene expression from non-E-box motifs

    by Chiara Nicoletti, Jimmy Massenet, Andreas P. Pintado-Urbanc, Leah J. Connor, Monica Nicolau, Swetha Sundar, Mingzhi Xu, Anthony Schmitt, Wenxin Zhang, Zesen Fang, et al.

    We report here on the identification of a previously unrecognized property of MYOD as a repressor of gene expression via E-box-independent chromatin binding during the process of somatic cell trans -differentiation into skeletal muscle. When ectopically expressed in proliferating human fibroblasts or endogenously induced in activated muscle stem cells (MuSCs), MYOD was detected at accessible regulatory elements of expressed genes, invariably leading to reduced chromatin accessibility and gene repression. At variance with conventional E-box-driven increased chromatin accessibility and H3K27 acetylation at previously silent loci of MYOD-activated genes, MYOD-mediated chromatin compaction and repression of transcription was associated with high occurrence of non-E-box motifs and did not lead to reduced levels of H3K27ac but coincided with reduced levels of H4 acetyl-methyl lysine modification (Kacme). Using MYOD mutants, we dissected the molecular mechanism of MYOD-mediated repression, whereby repression of mitogen-responsive and growth factor-responsive genes occurred via promoter binding, which requires a conserved domain within the first helix; conversely, repression of cell of origin/alternative lineage genes occurred via binding and decommissioning of distal regulatory elements such as superenhancers (SEs), required either the N-terminal activation domain or the two chromatin remodeling domains, and coincided with reduced strength of CTCF-mediated chromatin interactions. These data extend MYOD biological properties beyond the current dogma that restricts MYOD function to a monotone transcriptional activator. They also reveal an unprecedented functional versatility arising from alternative chromatin recruitment through E-box or non-E-box sequences, whereby genetic determinants dictate differential usage of MYOD functional domains.


  • Open Access

    Uncovering the isoform-resolution kinetic landscape of nonsense-mediated mRNA decay with EZbakR

    by Justin W. Mabin, Isaac W. Vock, Martin Machyna, Nazmul Haque, Poonam Thakran, Alexandra Zhang, Ganesha Rai, Isabelle Nathalie-Marie Leibler, James Inglese, Matthew D. Simon, et al.

    Cellular RNA levels are a product of synthesis and degradation kinetics, which can differ among transcripts of the same gene. An important cause of isoform-specific decay is the nonsense-mediated mRNA decay (NMD) pathway, which degrades transcripts with premature termination codons (PTCs) and other features. Understanding NMD functions requires strategies to quantify isoform kinetics; however, current approaches remain limited. Methods like nucleotide-recoding RNA-seq (NR-seq) enable insights into RNA kinetics, but existing bioinformatic tools do not provide robust, isoform-specific degradation rate constant estimates. We extend the EZbakR-suite by implementing a strategy to infer isoform-level kinetics from short-read NR-seq data. This approach uncovers unexpected variability in NMD efficiency among transcripts with conserved PTC-containing exons and rapid decay of a subset of mRNAs lacking PTCs. Our findings highlight the effects of competition between NMD and other decay pathways, provide mechanistic insights into established NMD efficiency correlates, and identify transcript features promoting efficient decay.


  • Open Access

    RBM15-MKL1 fusion protein promotes leukemia via m6A methylation and WNT pathway activation

    by Madeline Y. Mayday, Giulia Biancon, Manyi Wei, Christian Ramirez, Irene Moratti, Andreas P. Pintado-Urbanc, Lin Wang, Jether Amos Espinosa, Matthew D. Simon, Yaara Ofir-Rosenfeld, et al.

    Acute megakaryoblastic leukemia driven by the RBM15-MKL1 fusion protein (RM-AMKL) is the only known recurrent mutation involving the N6-methyladenosine (m6A) writer complex. Dysregulation of m6A modification affects RNA fate and is linked to oncogenesis. Inhibition of m6A deposition via inhibition of the METTL3 writer protein has anti-tumour activity, but the mechanism underlying its efficacy and cancer specificity remains unclear. We treated murine RM-AMKL cells with a novel METTL3 inhibitor, STM3675, and showed apoptosis in vitro and prolonged survival of mice transplanted with RM-AMKL, implicating m6A as an essential component of AMKL and identifying Wnt signalling as a key driver of leukemogenesis. To elucidate the mechanism by which m6A contributes to leukemogenesis we employed a multi-omic approach, combining transcriptome-wide assessment of RNA binding, methylation and turnover. We show for the first time that RM retains the RNA-binding and m6A-modifiying functions of its RBM15 component, while also selectively regulating distinct mRNA targets, particularly genes involved in Wnt signalling including Frizzled. Frizzled genes are upregulated by RM and downregulated in RM-AMKL cells in response to METTL3 inhibition, providing an m6A-dependent explanation for their upregulation. Direct Frizzled knockdown reduced RM-AMKL growth, which was partially rescued by treatment with a β-catenin agonist, underscoring a functional role of Wnt signalling in RM-AMKL. Human AMKLs show elevated Wnt pathway and Frizzled gene expression, highlighting the relevance of our work. Together, our findings reveal that RM-specific m6A modifications and activation of Wnt signalling are critical drivers of RM-AMKL, highlighting these pathways as potential therapeutic targets. Key Points: RM retains functional abilities of RBM15 and additionally interacts with Wnt-related transcripts to increase expression of Fzd proteins. The METTL3 writer complex and WNT signalling pathways are essential for RM-driven leukemia.


  • Open Access

    E-box independent chromatin recruitment turns MYOD into a transcriptional repressor

    by Chiara Nicoletti, Jimmy Massenet, Andreas P. Pintado-Urbanc, Leah J. Connor, Monica Nicolau, Swetha Sundar, Mingzhi Xu, Anthony Schmitt, Wenxin Zhang, Zesen Fang, et al.

    MYOD is an E-box sequence-specific basic Helix-Loop-Helix (bHLH) transcriptional activator that, when expressed in non-muscle cells, induces nuclear reprogramming toward skeletal myogenesis by promoting chromatin accessibility at previously silent loci. Here, we report on the identification of a previously unrecognized property of MYOD as repressor of gene expression, via E-box-independent chromatin binding within accessible genomic elements, which invariably leads to reduced chromatin accessibility. MYOD-mediated repression requires the integrity of functional domains previously implicated in MYOD-mediated activation of gene expression. Repression of mitogen-and growth factor-responsive genes occurs through promoter binding and requires a highly conserved domain within the first helix. Repression of cell-of-origin/alternative lineage genes occurs via binding and decommissioning of distal regulatory elements, such as super-enhancers (SE), which requires the N-terminal activation domain as well as two chromatin-remodeling domains and leads to reduced strength of CTCF-mediated chromatin interactions. Surprisingly, MYOD-mediated chromatin compaction and repression of transcription do not associate with reduction of H3K27ac, the conventional histone mark of enhancer or promoter activation, but with reduced levels of the recently discovered histone H4 acetyl-methyl lysine modification (Kacme). These results extend MYOD biological properties beyond the current dogma that restricts MYOD function to a monotone transcriptional activator and reveal a previously unrecognized functional versatility arising from an alternative chromatin recruitment through E-box or non-E-box sequences. The E-box independent repression of gene expression by MYOD might provide a promiscuous mechanism to reduce chromatin accessibility and repress cell-of-origin/alternative lineage and growth factor/mitogen-responsive genes to safeguard the integrity of cell identity during muscle progenitor commitment toward the myogenic lineage.